• Partial BACE Inhibition and Synaptic Transmission

  2026-08-28

  Satir et al. showed that partial β-secretase inhibition can reduce amyloid β secretion by up to 50% without measurably impairing synaptic transmission in cultured rat cortical neurons. The study supports exposure strategies that lower amyloid production while avoiding the broader functional disruption observed at stronger BACE inhibition.

• SHC-1 Inhibition and CFTR Surface Trafficking

  2026-08-27

  This 2026 study shows that MAPK/SHC-1-dependent internalization of CFTR is conserved across airway and intestinal epithelial models, while the response to SHC-1 inhibitors is strongly cell-type dependent. Its findings distinguish pathway conservation from pharmacological selectivity and caution against interpreting increased CFTR surface abundance in CFBE cells as a universally transferable rescue mechanism.

• Ionomycin Calcium Salt: A Mechanism-First Guide

  2026-08-27

  Ionomycin calcium salt is a calcium ionophore for dissecting how intracellular Ca2+ dynamics shape secretion, protein regulation, and apoptosis. This mechanism-first guide connects B5165-based calcium perturbation with DNA-repair-focused cancer assays while clarifying what the evidence does—and does not—support.

• Cytarabine (AraC): Applied Apoptosis Workflows

  2026-08-26

  Build more informative leukemia apoptosis experiments with Cytarabine by pairing dose–time profiling with deoxycytidine kinase, p53, caspase-3, and DNA-synthesis readouts. A practical bridge to viral cell-death research helps distinguish AraC-driven apoptosis from RIPK3/MLKL-associated inflammatory death without overstating what the evidence shows.

• Isochlorogenic acid A Hydrogel Research

  2026-08-26

  Translate Isochlorogenic acid A into practical natural-product, anti-infection, immunology, and wound-repair workflows. This guide pairs solvent-aware handling with a Fe(III)-co-assembled hydrogel strategy and evidence-based assay controls.

• TSPAN18–STIM1 Signaling in Prostate Cancer Bone Metastasis

  2026-08-25

  Zhou et al. identify TSPAN18 as a post-translational regulator of STIM1, showing that it protects STIM1 from TRIM32-mediated ubiquitination and sustains calcium entry that promotes prostate cancer bone metastasis. The work provides a mechanistic framework for studying protein stability, store-operated calcium entry, and metastatic behavior in prostate cancer models.

• Dabigatran Etexilate: Clinical Review and PK Insights

  2026-08-25

  Blommel and Blommel’s clinical review presents dabigatran etexilate as the first oral direct thrombin inhibitor marketed in the United States, emphasizing its prodrug activation, predictable anticoagulant response, and clinical utility across thromboembolic disorders. Its most important translational insight is that dabigatran etexilate activation and dabigatran metabolism do not depend on the cytochrome P450 system, while renal function remains central to dosing and safety.

• S Tag Peptide: Practical Fusion-Tag Workflow

  2026-08-24

  S Tag Peptide (SKU A6007) is a 15-amino-acid RNase A-derived tag used to support protein solubility improvement, recombinant protein detection, and antibody-based purification workflows. It should be evaluated as a genetically encoded fusion tag or validated antibody-recognition reagent, not as a standalone enzyme or independently folded structural peptide.

• DeferoxamineB Workflows for Cancer Research

  2026-08-24

  DeferoxamineB turns iron chelation into a practical mechanistic tool for separating ferroptosis from copper-driven cell death, while supporting apoptosis, autophagy, and oxidative-stress studies. This workflow guide translates a recent metabolic intervention strategy into reproducible assay design, dosing, controls, and troubleshooting.

• D-N-Acetylgalactosamine: Protocol and QC Guide

  2026-08-23

  D-N-Acetylgalactosamine (SKU B7904) provides a defined, high-purity amino sugar for aqueous or DMSO-based workflows involving glycoprotein constituents and brain heteropolysaccharides analysis. It should not be selected for ethanol-based protocols or for long-term storage of working solutions.

• CARM1 Peptide Therapy in Breast Cancer: Study Insights

  2026-08-22

  A 2026 Pharmacological Research study introduced Pi-CARM1, a selective peptide inhibitor of CARM1, and showed that its cell-permeable TAT-conjugated form suppresses breast cancer growth in cellular and mouse models. The findings connect CARM1 inhibition with estrogen receptor and interferon-regulated transcription, while supporting combination strategies for endocrine-resistant disease.

• Arctigenin, KEAP1-NRF2, and Doxorubicin Cardiotoxicity

  2026-08-21

  A 2026 Journal of Pharmaceutical Analysis study identifies arctigenin as a natural KEAP1-NRF2 pathway modulator that protects against doxorubicin-induced cardiac injury in cellular and mouse models. Its combination of natural-product screening, ferroptosis analysis, mitochondrial assessment, and target-level validation provides a useful framework for studying cardioprotective mechanisms, while clinical translation remains unproven.

• In Vitro Drug Response Metrics in Cancer

  2026-08-20

  Hannah R. Schwartz’s dissertation examines why relative viability and fractional viability should not be treated as interchangeable measures of anticancer drug response. Its central contribution is a measurement framework that separates proliferative inhibition from cell killing and considers their different temporal relationships, improving interpretation of in vitro cancer biology research.

• Indometacin Sodium: From COX Biology to Translation

  2026-08-20

  Indometacin Sodium is more than a conventional COX inhibitor: its sodium trihydrate form supports mechanistic studies spanning prostaglandin biology, pancreatic stellate cell activation, oligodendrocyte differentiation, and translational safety. This article outlines how researchers can move from a well-controlled inflammation assay to a mechanism-resolved development strategy.

• Fluorescein TSA Fluorescence System Kit Guide

  2026-08-19

  The Fluorescein TSA Fluorescence System Kit uses HRP-catalyzed deposition of fluorescein-labeled tyramide to increase localized fluorescence in IHC, ICC, and ISH. Its 494 nm excitation and 517 nm emission profile supports standard fluorescence microscopy, while its chemistry is suited to detecting low-abundance biomolecules when assay controls are carefully applied.

7940 records 1/530 page Next 12345 下5页 Last page